Security
Autolus Therapeutics plc American Depositary Share · AUTL
AUTLNASDAQotherCurrentCIK 1730463Updated Oct 6, 2026
Name history
Autolus Therapeutics Ltd · through Jun 8, 2018
AUTL price & chart
Loading TradingView…
NASDAQ:AUTL on TradingView ↗About the company
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
SCHEDULE 13D/A - filed by PPF Group a.s. regarding Autolus Therapeutics plc
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 661,947,000Source | 827,490,000Source | 493,226,000Source | 720,981,000Source | 853,620,000Source | 527,065,000Source | 746,338,000Source | 901,436,000Source | 589,068,000Source | 782,725,000Source | 459,971,000Source | 490,274,000Source |
| Property, Plant and Equipment, NetUSD | 66,851,000Source | 44,258,000Source | 60,523,000Source | 66,467,000Source | 32,860,000Source | 61,908,000Source | 57,970,000Source | 33,414,000Source | 63,563,000Source | 49,553,000Source | 34,667,000Source | 35,209,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 86,124,000Source | 657,067,000Source | 171,414,000Source | 123,825,000Source | 705,939,000Source | 130,925,000Source | 95,799,000Source | 758,529,000Source | 104,132,000Source | 227,380,000Source | 343,027,000Source | 382,436,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 0Source | 44,392,000Source | — | 0Source | 27,663,000Source | — | 0Source | 24,024,000Source | 15,000Source | — | 121,000Source |
| Inventory, NetUSD | 27,723,000Source | — | 33,431,000Source | 23,943,000Source | — | 33,233,000Source | 14,647,000Source | — | 33,209,000Source | 4,138,000Source | — | — |
| Assets, CurrentUSD | 514,577,000Source | 718,114,000Source | 336,091,000Source | 574,250,000Source | 758,600,000Source | 368,835,000Source | 615,773,000Source | 804,298,000Source | 435,915,000Source | 660,929,000Source | 393,885,000Source | 425,771,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 85,339,000Source | 59,577,000Source | 55,142,000Source | 67,877,000Source | 51,641,000Source | 77,012,000Source | 68,782,000Source | 44,754,000Source | 76,469,000Source | 67,343,000Source | 50,530,000Source | 43,010,000Source |
| Operating Lease, Right-of-Use AssetUSD | 56,625,000Source | 60,503,000Source | 74,111,000Source | 58,619,000Source | 57,678,000Source | 72,563,000Source | 56,250,000Source | 59,126,000Source | 64,940,000Source | 55,498,000Source | 26,861,000Source | 23,210,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 396,495,000Source | 350,525,000Source | 418,387,000Source | 374,517,000Source | 325,776,000Source | 418,239,000Source | 375,230,000Source | 319,406,000Source | 410,939,000Source | 355,400,000Source | 193,051,000Source | 191,600,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 1,566,662,000Source | 1,549,351,000Source | 1,578,271,000Source | 1,562,774,000Source | 1,545,146,000Source | 1,573,673,000Source | 1,558,469,000Source | 1,542,086,000Source | 1,570,107,000Source | 1,555,593,000Source | 1,010,041,000Source | 1,007,625,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,296,420,000Source | -1,071,618,000Source | -1,497,461,000Source | -1,217,302,000Source | -989,524,000Source | -1,458,350,000Source | -1,169,385,000Source | -931,252,000Source | -1,386,752,000Source | -1,099,224,000Source | -709,990,000Source | -670,179,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,920,000Source | -898,000Source | -6,101,000Source | 862,000Source | -27,908,000Source | -6,627,000Source | -18,106,000Source | -28,934,000Source | -5,356,000Source | -29,174,000Source | -33,257,000Source | -38,898,000Source |
| Stockholders' Equity Attributable to ParentUSD | 265,452,000Source | 476,965,000Source | 74,839,000Source | 346,464,000Source | 527,844,000Source | 108,826,000Source | 371,108,000Source | 582,030,000Source | 178,129,000Source | 427,325,000Source | 266,920,000Source | 298,674,000Source |
| Liabilities and EquityUSD | 661,947,000Source | 827,490,000Source | 493,226,000Source | 720,981,000Source | 853,620,000Source | 527,065,000Source | 746,338,000Source | 901,436,000Source | 589,068,000Source | 782,725,000Source | 459,971,000Source | 490,274,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 83,071,000Source | 52,474,000Source | 68,790,000Source | 68,151,000Source | 40,904,000Source | 63,599,000Source | 66,615,000Source | 43,985,000Source | 73,440,000Source | 60,743,000Source | 39,637,000Source | 46,366,000Source |
| Operating Lease, Liability, CurrentUSD | 4,828,000Source | 3,568,000Source | 5,789,000Source | 3,277,000Source | 4,227,000Source | 3,061,000Source | 2,974,000Source | 4,818,000Source | 4,565,000Source | 2,998,000Source | 4,821,000Source | 5,038,000Source |
| Accounts Payable, CurrentUSD | 10,967,000Source | 1,418,000Source | 1,366,000Source | 5,408,000Source | 1,098,000Source | 1,872,000Source | 4,457,000Source | 1,399,000Source | 3,083,000Source | 1,969,000Source | 353,000Source | 531,000Source |
| Operating Lease, Liability, NoncurrentUSD | 61,007,000Source | 48,661,000Source | 77,723,000Source | 61,258,000Source | 45,794,000Source | 76,895,000Source | 54,734,000Source | 46,518,000Source | 66,822,000Source | 49,631,000Source | 22,495,000Source | 19,218,000Source |
| Other Liabilities, NoncurrentUSD | 472,000Source | 447,000Source | 474,000Source | 477,000Source | 415,000Source | 477,000Source | 444,000Source | 409,000Source | 477,000Source | 426,000Source | 114,000Source | 116,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 52,264,000Source | 47,488,000Source | 48,735,000Source | 51,366,000Source | 35,579,000Source | 46,766,000Source | 49,659,000Source | 37,768,000Source | 55,792,000Source | 52,276,000Source | 34,463,000Source | 40,797,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 2,209,000Source | 1,992,000Source | 8,296,000Source | 7,554,000Source | 6,565,000Source | 7,422,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 3,632,000Source | 14,335,000Source | 24,158,000Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,541,000Source | 10,099,000Source | 40,250,000Source | 4,229,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,173,000Source | 1,862,000Source | 1,300,000Source | 1,590,000Source | -509,000Source | 22,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -631,000Source | -175,000Source | -987,000Source | -212,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -65,317,000Source | -75,565,000Source | -283,568,000Source | -206,271,000Source | -145,587,000Source | -112,308,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 96,151,000Source | -59,547,000Source | 158,458,000Source | -394,552,000Source | -10,986,000Source | -10,841,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 2,688,000Source | 8,243,000Source | 19,043,000Source | 22,075,000Source | 10,986,000Source | 10,841,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -2,062,000Source | 0Source | -4,339,000Source | 589,554,000Source | -883,000Source | 223,610,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 26,783,000Source | -131,554,000Source | -123,170,000Source | -11,530,000Source | -142,426,000Source | 72,085,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 87,622,000Source | 658,537,000Source | 172,910,000Source | 125,332,000Source | 132,418,000Source | 97,251,000Source | 105,635,000Source | 228,805,000Source | 240,335,000Source | 382,761,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 209,000Source | 9,000Source | 1,968,000Source | 2,391,000Source | — | -19,573,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -1,989,000Source | 3,558,000Source | 6,279,000Source | -261,000Source | 15,030,000Source | -28,376,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,835,000Source | 4,020,000Source | 4,595,000Source | 4,293,000Source | 3,565,000Source | 2,867,000Source | 14,438,000Source | 15,472,000Source | 11,250,000Source | 12,014,000Source |
| Amortization of Intangible AssetsUSD | — | — | 500,000Source | 0Source | 500,000Source | 300,000Source | 490,000Source | 285,000Source | 1,518,000Source | 162,000Source | 0Source | 65,000Source |
| DepreciationUSD | — | — | 2,100,000Source | 1,900,000Source | 2,200,000Source | 2,100,000Source | 2,200,000Source | 1,900,000Source | 8,300,000Source | 7,600,000Source | 6,600,000Source | 7,300,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -911,000Source | -11,884,000Source | 460,000Source | 1,499,000Source | -2,667,000Source | 1,181,000Source | 2,163,000Source | -989,000Source | 2,600,000Source | 1,800,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -3,511,000Source | 1,896,000Source | 3,167,000Source | -1,898,000Source | 7,604,000Source | -3,996,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | 0Source | -223,000Source | — | 0Source | — | -3,000Source | — | -223,000Source | -3,791,000Source | -515,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -2,000Source | -3,000Source | -14,000Source | -223,000Source | -3,791,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | 0Source | -176,000Source | -95,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | — | 27,330,000Source | — | — | — | — | — | — | 46,745,000Source | 31,899,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 532,000Source | 22,000Source | 465,000Source | 397,000Source | 863,000Source | 2,225,000Source | 1,972,000Source | 1,528,000Source | -19,500Source | -24,366,000Source |
| InterestExpenseNonoperatingUSD | — | — | 10,520,000Source | 10,686,000Source | -2,674,000Source | -6,829,000Source | 11,124,000Source | 10,143,000Source | 36,670,000Source | 9,294,000Source | — | — |
| Inventory Write-downUSD | — | — | 4,300,000Source | 0Source | 1,200,000Source | 2,500,000Source | 2,046,000Source | 0Source | 12,279,000Source | 0Source | — | — |
| Investment Income, InterestUSD | — | — | 4,382,000Source | 8,320,000Source | 1,877,000Source | 5,234,000Source | 2,469,000Source | 6,137,000Source | 18,980,000Source | 32,355,000Source | 13,505,000Source | 1,708,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -79,118,000Source | -82,094,000Source | -39,111,000Source | -47,917,000Source | -71,598,000Source | -70,161,000Source | -287,528,000Source | -220,662,000Source | -208,383,000Source | -148,839,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -79,118,000Source | -82,094,000Source | -39,111,000Source | -47,917,000Source | -71,598,000Source | -70,161,000Source | -287,528,000Source | -220,662,000Source | -208,383,000Source | -148,839,000Source |
| Nonoperating Income (Expense)USD | — | — | -6,965,000Source | -14,196,000Source | 5,192,000Source | 13,697,000Source | -11,222,000Source | -2,696,000Source | -15,012,000Source | 22,292,000Source | -28,701,000Source | -5,159,000Source |
| Operating Lease, Impairment LossUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 349,000Source | 414,000Source | 382,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 84,000Source | 54,000Source | 181,000Source | 135,000Source | 100,000Source | 129,000Source | 515,000Source | 220,000Source | 2,861,000Source | 2,038,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 0Source | 549,977,000Source | 0Source | 163,854,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 0Source | 602,000Source | 27,000Source | 117,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 21,194,000Source | 0Source | 45,689,000Source | 20,923,000Source | 26,218,000Source | 8,982,000Source | 75,388,000Source | 10,120,000Source | — | — |
| Cost of RevenueUSD | — | — | 28,643,000Source | 0Source | 20,468,000Source | 24,445,000Source | 24,568,000Source | 17,951,000Source | 96,369,000Source | 11,387,000Source | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 36,280,000Source | 27,330,000Source | 41,161,000Source | 30,265,000Source | 39,953,000Source | 29,537,000Source | 131,874,000Source | 101,086,000Source | — | — |
| Operating Income (Loss)USD | — | — | -71,621,000Source | -67,876,000Source | -43,838,000Source | -61,217,000Source | -59,513,000Source | -65,240,000Source | -270,544,000Source | -241,426,000Source | -179,701,000Source | -168,046,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 84,000Source | 54,000Source | 181,000Source | 135,000Source | 100,000Source | 129,000Source | 515,000Source | 220,000Source | 2,861,000Source | 2,038,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -78,586,000Source | -82,072,000Source | -38,646,000Source | -47,520,000Source | -70,735,000Source | -67,936,000Source | -285,556,000Source | -219,134,000Source | -208,402,000Source | -173,205,000Source |
| Income Tax Expense (Benefit)USD | — | — | 532,000Source | 22,000Source | 465,000Source | 397,000Source | 863,000Source | 2,225,000Source | 1,972,000Source | 1,528,000Source | -19,500Source | -24,366,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -79,118,000Source | -82,094,000Source | -39,111,000Source | -47,917,000Source | -71,598,000Source | -70,161,000Source | -287,528,000Source | -220,662,000Source | -208,383,000Source | -148,839,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.3Source | -0.31Source | -0.15Source | -0.18Source | -0.27Source | -0.26Source | -1.08Source | -0.86Source | -1.2Source | -1.57Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.3Source | -0.31Source | -0.15Source | -0.18Source | -0.27Source | -0.26Source | -1.08Source | -0.86Source | -1.2Source | -1.57Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 266,141,431Source | 266,084,589Source | 266,158,829Source | 266,141,411Source | 266,143,425Source | 266,126,548Source | 266,138,224Source | 255,161,038Source | 173,941,926Source | 94,993,400Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 266,141,431Source | 266,084,589Source | 266,158,829Source | 266,141,411Source | 266,143,425Source | 266,126,548Source | 266,138,224Source | 255,161,038Source | 173,941,926Source | 94,993,400Source |
| Interest Expense (non-operating)USD | — | — | 10,520,000Source | 10,686,000Source | -2,674,000Source | -6,829,000Source | 11,124,000Source | 10,143,000Source | 36,670,000Source | 9,294,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 500,000Source | 0Source | 500,000Source | 300,000Source | 490,000Source | 285,000Source | 1,518,000Source | 162,000Source | 0Source | 65,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,603,000Source | 1,703,000Source | 968,000Source | -24,154,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -911,000Source | -11,884,000Source | 460,000Source | 1,499,000Source | -2,667,000Source | 1,181,000Source | 2,163,000Source | -989,000Source | 2,600,000Source | 1,800,000Source |
| General and Administrative ExpenseUSD | — | — | — | 27,330,000Source | — | — | — | — | — | — | 46,745,000Source | 31,899,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -290,109,000Source | -221,661,000Source | -209,766,000Source | — |
| Interest ExpenseUSD | — | — | 10,520,000Source | 10,686,000Source | -2,674,000Source | -6,829,000Source | 11,124,000Source | 10,143,000Source | 36,670,000Source | 9,294,000Source | 45,067,000Source | 8,905,000Source |
| Investment Income, InterestUSD | — | — | 4,382,000Source | 8,320,000Source | 1,877,000Source | 5,234,000Source | 2,469,000Source | 6,137,000Source | 18,980,000Source | 32,355,000Source | 13,505,000Source | 1,708,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -79,118,000Source | -82,094,000Source | -39,111,000Source | -47,917,000Source | -71,598,000Source | -70,161,000Source | -287,528,000Source | -220,662,000Source | -208,383,000Source | -148,839,000Source |
| Nonoperating Income (Expense)USD | — | — | -6,965,000Source | -14,196,000Source | 5,192,000Source | 13,697,000Source | -11,222,000Source | -2,696,000Source | -15,012,000Source | 22,292,000Source | -28,701,000Source | -5,159,000Source |
| Research and Development ExpenseUSD | — | — | 27,892,000Source | 40,323,000Source | 27,898,000Source | 27,430,000Source | 21,210,000Source | 26,734,000Source | 117,689,000Source | 138,436,000Source | 130,481,000Source | 141,992,000Source |
Offerings
Registration 333-298910
Registration 333-295003
Registration 333-295004
Filing attachments
ea030383301ex99-1.htm · SCHEDULE 13D/A · 2026-08-28
Exhibit 99.1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with respect to securities of Autolus Therapeutics plc…
Read attachment ↗d156965dex41.htm · 8-K · 2026-08-03
EX-4.1 2 d156965dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE SECURITIES ACT AND IS…
Read attachment ↗d113906dex991.htm · 8-K · 2026-04-29
EX-99.1 2 d113906dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical trial patients in 2026 Autolus reiterates full year 2026 AUCATZYL® net product revenue of $120 million to $135 m…
Read attachment ↗